Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosomeEl-Zimaity, M.M.T. ; Kantarjian, H. ; Talpaz, M. ; O'Brien, S. ; Giles, F. ; Garcia-Manero, G. ; Verstovsek, S. ; Thomas, D. ; Ferrajoli, A. ; Hayes, K. ; Nebiyou Bekele, B. ; Zhou, X. ; Rios, M.B. ; Glassman, A.B. ; Cortes, J.E.
AbstractFive to 10 per cent of patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukaemia (CML) have variant translocations involving chromosomes other than 9 and 22. We investigated the characteristics and outcome of patients with variant translocations treated with imatinib. Among 721 patients, 44 (6%) had variant translocations, involving one (n = 39) or two (n = 4) additional chromosomes. Nineteen patients (44%) were in chronic (12 previously untreated), 24 (55%) in accelerated and one (2%) in blastic phase. A major cytogenetic response was achieved in 14 (74%) patients treated in chronic phase and in 14 (58%) treated in accelerated phase. Six of 13 (46%) evaluable patients had deletion of derivative chromosome 9, and there was a trend for a lower response rate in these patients. We compared the 43 patients in chronic or accelerated phase to 678 patients with classic Ph treated with imatinib. The only significant difference in clinical characteristics was a higher frequency of accelerated phase among those with variant translocations (56%) compared with those with classic translocations (38%). No differences in outcome were evident. In a multivariate analysis, variant Ph translocations had no impact in response rate, overall survival or duration of response. We conclude that patients with variant Ph translocations have a similar prognosis to those with classic Ph translocations when treated with imatinib.
|Issue Date||2004||Journal||British Journal of Haematology||URI||http://research.asu.edu.eg/handle/123456789/1687||DOI||2
Recommend this item
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.